Bibliography
- Foss FM. DAB389IL-2 (Ontak): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 2000;2:110-6
- Smith KA. The structure of IL-2 bound to the three chains of the IL2 receptor and how signaling occurs. Med Immunol 2006;5:3
- Minami Y, KoNo T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993;11:245-68
- Eklund JW, Kuzel TM. Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther 2005;5:33-8
- Caliquiri MA, Zmuidzinas A, Manley TJ, Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptor. J Exp Med 1990;171(5):1509-26
- Dang NH, Pro B, Hagemeister FB, Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007;136:439-47
- Research discovers CTCL incidence rising in US. Birmingham, Michigan, Cutaneous T-Cell Lymphoma Foundation, Fall 2007 forum. Available from: www.clfoundation.org/publications/forum_fall_07.pdf. [Last accessed 21 September 2009]
- Cutaneous T-cell lymphoma – treatment options. New York, USA: Lymphoma.about.com, updated April 25, 2007. Available from: http://lymphoma.about.com/od/treatment/p/ctcltreatment.htm [Last accessed 21 September 2009]
- Schwartz RA, Lambert WC. Cutaneous T-cell lymphoma: treatment and medication. Omaha, Nebraska, USA: medscape, updated March 19, 2009. Available from: http://emedicine.medscape.com/article/1098342-treatment [Last accessed 21 September 2009]
- LeMaistre CF, Saleh MN, Kuzel TM, Phase 1 trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998;91:399-405
- Olsen E, Duvic M, Frankel A, Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88
- Vidulich K, Jones D, Duvic M. Cutaneous gamma/δ T-cell lymphoma treated with radiation and denileukin diftitox. Clin Lymphoma Myeloma 2008;8:55-8
- International T-cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30
- Morton LM, Wang SS, Devesa SS, Lymphoma incidence patterns by WHO subtype in United States, 1992-2001. Blood 2006;107:265-76
- The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-18
- Eklund JW, Weller E, Kuzel TM, Phase II study of denileukin diftitox for previously treated low grade non-Hodgkin's lymphoma: E1497 final report. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(Suppl 1):6684
- Wong BY, Ma Y, Fitzwilson R, Dang NH. De novo maintenance therapy with denileukin diftitox (Ontak®) in a patient with peripheral T-cell lymphoma is associated with prolonged remission. Am J Hematol 2008;83:596-8
- LeMaistre CF, Meneghetti C, Rosenblum M, Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992;79:2547-54
- Wainscoat B, Salas C, Rich JD. Human T-cell lymphotrophic viruses. Omaha, Nebraska, USA: Medscape, updated Jul 13, 2006. Available from: http://emedicine.medscape.com/article/219285-overview [Last accessed 21 September 2009]
- Di Venuti G, Nawgiri R, Foss F. Denileukin diftitox and hyper-CVAD in treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. Clin Lymphoma Myeloma 2003;4:176-8
- American Cancer Society. Cancer Facts and Figures 2008. American Cancer Society: Atlanta 2008. Available from: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf [Last accessed 21 September 2009]
- Frankel AE, Fleming DR, Powell BL, Gartenhaus R. DAB389IL-2 (Ontak) fusion protein therapy of chronic lymphocytic leukemia. Expert Opin Biol Ther 2003;3:179-86
- Lilly M, Kuriakose P, Turturro F, A phase II study of denileukin diftitox (Ontak) in patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(Suppl 1):6649
- Frankel AE, Surendranathan A, Black JH, Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer 2006;106:2158-64
- Non-Hodgkin's Lymphoma. National Cancer Institute: US National Institutes of Health 2009. Available from: www.cancer.gov/cancertopics/types/non-hodgkin. [Last accessed 21 September 2009]
- Kuzel TM. DAB389IL-2 (Denileukin diftitox, Ontak): review of clinical trials to date. Clin Lymphoma 2000;1(Suppl 1):S33-6
- Dang NH, Hagemeister FB, Pro B, Phase II study of Denileukin Diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004;22:4095-102
- Dang NH, Fayad L, McLaughlin P, Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell NHL. Br J Haematol 2007;138:502-5
- Rasku MA, Clem AL, Telang S, Transient T cell depletion causes regression of melanoma metastasis. J Transl Med 2008;6:12
- Mahnke K, Schonfeld K, Fondel S, Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007;120(12):2723-33
- Attia P, Maker AV, Haworth LR, Inability of fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005;28(6):582-92
- Ruter J, Barnett BG, Kryczek I, Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci 2009;14:1761-70
- Barnett B, Kryczek I, Cheng P, Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005;54(6):369-77
- LeMaistre CF. DAB389IL-2 (Denileukin diftitox, Ontak): other potential uses. Clin Lymphoma 2000;l(Suppl 1):S37-40
- Shaughnessy PJ, Bachier C, Grimly M, Denileukin diftitox for treatment of steroid-resistant acute graft-vs-host disease. Biol Blood Marrow Transplant 2005;11:188-93
- Martin A, Gutierrez E, Muglia J, A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB389IL-2) in patients with severe psoriasis. J Am Acad Dermatol 2001;45:871-81
- Kim BH, Yoon JH, Myung SJ, Enhanced interleukin-2 diphtheria toxin conjugate-induced growth suppression in retinoic acid-treated hypoxic hepatocellular carcinoma cells. Cancer Lett 2009;274:259-65